# Phase III Study of CG100649 in Osteoarthritis Patients

> **NCT01765296** · PHASE3 · COMPLETED · sponsor: **CrystalGenomics, Inc.** · enrollment: 362 (actual)

## Conditions studied

- Localized Primary Osteoarthritis of Hip
- Localized Primary Osteoarthritis of Knee

## Interventions

- **DRUG:** CG100649
- **DRUG:** Celecoxib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01765296
- **Lead sponsor:** CrystalGenomics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-12
- **Final completion:** 2014-04
- **Target enrollment:** 362 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01765296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01765296, "Phase III Study of CG100649 in Osteoarthritis Patients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01765296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*